Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.

Published on Aug 14, 2019in Cancers6.126
· DOI :10.3390/CANCERS11081168
Haozhong Ding3
Estimated H-index: 3
(KTH: Royal Institute of Technology),
Mohamed Altai19
Estimated H-index: 19
(Uppsala University)
+ 4 AuthorsAnna Orlova53
Estimated H-index: 53
(Uppsala University)
Sources
Abstract
Affibody molecules are small affinity-engineered scaffold proteins which can be engineered to bind to desired targets. The therapeutic potential of using an affibody molecule targeting HER2, fused to an albumin-binding domain (ABD) and conjugated with the cytotoxic maytansine derivate MC-DM1 (AffiDC), has been validated. Biodistribution studies in mice revealed an elevated hepatic uptake of the AffiDC, but histopathological examination of livers showed no major signs of toxicity. However, previous clinical experience with antibody drug conjugates have revealed a moderate- to high-grade hepatotoxicity in treated patients, which merits efforts to also minimize hepatic uptake of the AffiDCs. In this study, the aim was to reduce the hepatic uptake of AffiDCs and optimize their in vivo targeting properties. We have investigated if incorporation of hydrophilic glutamate-based spacers adjacent to MC-DM1 in the AffiDC, (ZHER2:2891)2–ABD–MC-DM1, would counteract the hydrophobic nature of MC-DM1 and, hence, reduce hepatic uptake. Two new AffiDCs including either a triglutamate–spacer–, (ZHER2:2891)2–ABD–E3–MC-DM1, or a hexaglutamate–spacer–, (ZHER2:2891)2–ABD–E6–MC-DM1 next to the site of MC-DM1 conjugation were designed. We radiolabeled the hydrophilized AffiDCs and compared them, both in vitro and in vivo, with the previously investigated (ZHER2:2891)2–ABD–MC-DM1 drug conjugate containing no glutamate spacer. All three AffiDCs demonstrated specific binding to HER2 and comparable in vitro cytotoxicity. A comparative biodistribution study of the three radiolabeled AffiDCs showed that the addition of glutamates reduced drug accumulation in the liver while preserving the tumor uptake. These results confirmed the relation between DM1 hydrophobicity and liver accumulation. We believe that the drug development approach described here may also be useful for other affinity protein-based drug conjugates to further improve their in vivo properties and facilitate their clinical translatability.
Download
📖 Papers frequently viewed together
17 Citations
20203.27Molecules
3 Authors (Javad Garousi, ..., M. Altai)
2 Citations
26 Citations
References39
Newest
#1Kei Yamada (Kadai: Kagoshima University)H-Index: 4
#2Yuji Ito (Kadai: Kagoshima University)H-Index: 16
: Antibody-drug conjugates (ADCs), which consist of three components, antibody, linker, and payload, can function as "magic bullets". These conjugates offer the ability to target drug delivery to specific cells, based on cell-specific recognition and the binding of an antigen by a monoclonal antibody (mAb). In particular, by delivering a cytotoxic payload to cancer cells, ADCs are expected to provide a breakthrough in oncology treatments by providing a way to increase efficacy and decrease toxic...
20 CitationsSource
#1Meghdad Abdollahpour-Alitappeh (BMSU: Baqiyatallah University of Medical Sciences)H-Index: 9
#2Majid Lotfinia (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 8
Last. Nader Bagheri (Shahrekord University of Medical Sciences)H-Index: 16
view all 13 authors...
Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody–drug conjugates (ADCs), in which a monoclonal antibody (mAb) is conjugated to biologically active drugs through chemical linkers, have emerged as a promising class of anticancer treatment agents, being one of the fastest growing fields in cancer therapy. The failure of early ADCs led researchers to explore strategies to develop more effective and improved ADCs with lower ...
65 CitationsSource
#1Chunlin Zhuang ('SMMU': Second Military Medical University)H-Index: 14
#2Xianghong Guan (UMN: University of Minnesota)H-Index: 1
Last. Zhenyuan Miao ('SMMU': Second Military Medical University)H-Index: 29
view all 6 authors...
Abstract Targeted therapy has become an effective strategy of precision medicine for improving cancer treatment. Selectivity improvement is always popular in modern oncology because of decreased side effects in conventional cancer chemotherapy. The use of antibody-drug conjugates (ADC), a robust strategy for targeted therapy, applies antibodies to selectively deliver a potent cytotoxic compound to tumor cells and thus improve the therapeutic efficacy of the chemotherapeutic agents. Three ADC pro...
28 CitationsSource
#1Alexis D. Leal (CU: University of Colorado Boulder)H-Index: 8
#2Anuradha Krishnamurthy (CU: University of Colorado Boulder)H-Index: 4
Last. Wells A. Messersmith (CU: University of Colorado Boulder)H-Index: 59
view all 4 authors...
ABSTRACTIntroduction: Antibody drug conjugates (ADCs) represent a developing class of anticancer therapeutics which are designed to selectively deliver a cytotoxic payload to tumors, while limiting...
3 CitationsSource
#1Daniel A. Richards (UCL: University College London)H-Index: 8
The field of targeted therapeutics has benefitted immeasurably from the development of high-affinity antibodies. These important ligands have facilitated the development of effective therapies, particularly when conjugated to potent cytotoxic payloads i.e. in antibody–drug conjugates (ADCs). The success of ADCs is evidenced by rapid adoption within the pharmaceuticals community; many major companies have dedicated ADC research programmes. However, despite the advantages, the field of ADCs has fa...
24 CitationsSource
#1Mohamed Altai (Uppsala University)H-Index: 19
#2Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 8 authors...
Abstract Patients with HER2-positive tumors often suffer resistance to therapy, warranting development of novel treatment modalities. Affibody molecules are small affinity proteins which can be engineered to bind to desired targets. They have in recent years been found to allow precise targeting of cancer specific molecular signatures such as the HER2 receptor. In this study, we have investigated the potential of an affibody molecule targeting HER2, ZHER2:2891, conjugated with the cytotoxic mayt...
17 CitationsSource
#1Mohamed Altai (Uppsala University)H-Index: 19
#2Charles Dahlsson Leitao (KTH: Royal Institute of Technology)H-Index: 6
Last. Anna Orlova (Uppsala University)H-Index: 53
view all 9 authors...
Overexpression of human epidermal growth factor receptor type 3 (HER3) is associated with tumour cell resistance to HER-targeted therapies. Monoclonal antibodies (mAbs) targeting HER3 are currently being investigated for treatment of various types of cancers. Cumulative evidence suggests that affibody molecules may be appropriate alternatives to mAbs. We previously reported a fusion construct (3A3) containing two HER3-targeting affibody molecules flanking an engineered albumin-binding domain (AB...
10 CitationsSource
#1William D. Hedrich (UMB: University of Maryland, Baltimore)H-Index: 4
#1William D. Hedrich (UMD: University of Maryland, College Park)H-Index: 1
Last. Hazem E. Hassan (UMD: University of Maryland, College Park)H-Index: 16
view all 5 authors...
Antibody–drug conjugates are an emerging class of biopharmaceuticals changing the landscape of targeted chemotherapy. These conjugates combine the target specificity of monoclonal antibodies with the anti-cancer activity of small-molecule therapeutics. Several antibody–drug conjugates have received approval for the treatment of various types of cancer including gemtuzumab ozogamicin (Mylotarg®), brentuximab vedotin (Adcetris®), trastuzumab emtansine (Kadcyla®), and inotuzumab ozogamicin, which r...
26 CitationsSource
#1Maryam Oroujeni (Uppsala University)H-Index: 7
#2Ken G. Andersson (Uppsala University)H-Index: 12
Last. John Löfblom (KTH: Royal Institute of Technology)H-Index: 24
view all 10 authors...
Epidermal growth factor receptor (EGFR) is overexpressed in a number of cancers and is the molecular target for several anti-cancer therapeutics. Radionuclide molecular imaging of EGFR expression s ...
10 CitationsSource
#1Rudo Simeon (A&M: Texas A&M University)H-Index: 7
#2Zhilei Chen (A&M: Texas A&M University)H-Index: 17
Antibodies have proved to be a valuable mode of therapy for numerous diseases, mainly owing to their high target binding affinity and specificity. Unfortunately, antibodies are also limited in several respects, chief amongst those being the extremely high cost of manufacture. Therefore, non-antibody binding proteins have long been sought after as alternative therapies. New binding protein scaffolds are constantly being designed or discovered with some already approved for human use by the FDA. T...
64 CitationsSource
Cited By3
Newest
#1Hongrui Tian (Soochow University (Suzhou))H-Index: 1
#2Ya-Kui Huang (Soochow University (Suzhou))
Last. Peihong Ni (Soochow University (Suzhou))H-Index: 26
view all 5 authors...
In the treatment of tumor-targeted small-molecule anti-cancer drugs, antibody-mediated therapies, especially for antibody-drug conjugates (ADCs), have revealed great latent force. However, the ther...
Source
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 10
view all 8 authors...
Affibody molecules hold great promise as carriers of cytotoxic drugs for cancer therapy due to their typically high affinity, easy production, and inherent control of the drug molecules' loading and spatial arrangement. Here, the impact of increasing the drug load from one to three on the properties of an affibody drug conjugate targeting the human epidermal growth factor receptor 2 (HER2) was investigated. The affibody carrier was recombinantly expressed as a fusion to an albumin-binding domain...
Source
#1Tianqi XuH-Index: 2
#2Haozhong DingH-Index: 3
Last. Torbjörn GräslundH-Index: 21
view all 7 authors...
The human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in a variety of cancers and therapies targeting HER2 are routinely used in the clinic. Recently, small engineered scaffold proteins, such as affibody molecules, have shown promise as carriers of cytotoxic drugs, and these drug conjugates may become complements or alternatives to the current HER2-targeting therapies. Here, we investigated if a monovalent HER2-binding affibody molecule, ZHER2:2891, fused with a plasma ...
1 CitationsSource